Gateway Investment Advisers LLC decreased its stake in shares of Allergan plc (NYSE:AGN) by 0.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 235,196 shares of the company’s stock after selling 1,344 shares during the quarter. Gateway Investment Advisers LLC owned about 0.07% of Allergan worth $38,473,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the business. Howard Hughes Medical Institute purchased a new stake in shares of Allergan in the 2nd quarter valued at $103,000. Cable Hill Partners LLC boosted its holdings in shares of Allergan by 255.2% in the 3rd quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock valued at $106,000 after acquiring an additional 370 shares during the last quarter. Rockefeller Financial Services Inc. boosted its holdings in shares of Allergan by 283.7% in the 3rd quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock valued at $111,000 after acquiring an additional 400 shares during the last quarter. Massey Quick & Co. LLC boosted its holdings in shares of Allergan by 334.8% in the 2nd quarter. Massey Quick & Co. LLC now owns 500 shares of the company’s stock valued at $122,000 after acquiring an additional 385 shares during the last quarter. Finally, Pacific Center for Financial Services boosted its holdings in shares of Allergan by 1.3% in the 2nd quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after acquiring an additional 7 shares during the last quarter. Institutional investors and hedge funds own 81.26% of the company’s stock.
Shares of Allergan plc (NYSE AGN) traded down $0.94 during midday trading on Wednesday, reaching $177.72. 1,285,129 shares of the company were exchanged, compared to its average volume of 2,539,890. Allergan plc has a 12-month low of $160.07 and a 12-month high of $256.80. The stock has a market capitalization of $59,420.00, a P/E ratio of -7.87, a PEG ratio of 1.30 and a beta of 1.11. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.18 and a quick ratio of 1.08.
Allergan (NYSE:AGN) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.06 by $0.09. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. The firm had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the prior year, the firm posted $3.32 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. equities analysts predict that Allergan plc will post 16.27 earnings per share for the current fiscal year.
Allergan declared that its board has initiated a stock buyback plan on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.
Several analysts have recently commented on the stock. UBS Group set a $250.00 price objective on shares of Allergan and gave the company a “buy” rating in a report on Wednesday, January 10th. Vetr downgraded shares of Allergan from a “buy” rating to a “hold” rating and set a $180.97 price objective on the stock. in a report on Wednesday, January 10th. Deutsche Bank reaffirmed a “buy” rating and issued a $215.00 price objective on shares of Allergan in a report on Tuesday, January 9th. Citigroup dropped their price objective on shares of Allergan to $215.00 and set a “buy” rating on the stock in a report on Tuesday, January 9th. Finally, Wells Fargo & Co set a $245.00 price objective on shares of Allergan and gave the company a “buy” rating in a report on Friday, January 5th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $226.95.
In related news, Director Chris W. Bodine acquired 3,030 shares of the firm’s stock in a transaction on Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, with a total value of $499,253.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Brent L. Saunders acquired 4,600 shares of the firm’s stock in a transaction on Wednesday, December 6th. The shares were bought at an average cost of $164.74 per share, for a total transaction of $757,804.00. The disclosure for this purchase can be found here. Insiders have purchased 17,630 shares of company stock worth $2,890,057 over the last three months. 0.36% of the stock is currently owned by insiders.
WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/17/allergan-plc-agn-holdings-cut-by-gateway-investment-advisers-llc.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.